Government-backed Aimdbio Secures $1.4B Tech Deal, Hits $2.8B Market Cap
Creatrip Team
a month ago
Aimdbio, a South Korean biotech nurtured by government startup discovery and drug-development R&D programs, achieved a KRW 1.4 trillion (about $1.4 billion) technology licensing deal with global firm Boehringer Ingelheim and reached a KRW 2.8 trillion market capitalization on its KOSDAQ listing. The company develops next-generation antibody-drug conjugates (ADC) — therapies that link antibodies to potent cell-killing drugs to target cancer cells more precisely (ADC: antibody-drug conjugate) — aiming to improve efficacy and safety where traditional chemotherapy or single-antibody treatments fall short. Founded from a lab team that joined the “Texcore” startup exploration (Texcore: a Korean program validating lab technologies’ market value) in 2017, Aimdbio progressed via multi-agency national drug-development R&D support to advance preclinical work and build a clinical pipeline, now recognized as a model of public research commercialization and K-bio success.
